Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blockers for heart failure: why, which, when, and where.

John G F Cleland1

  • 1Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom. j.g.cleland@medschool.hull.ac.uk

The Medical Clinics of North America
|April 16, 2003
PubMed
Summary

Beta-blockers effectively treat heart failure from left ventricular (LV) systolic dysfunction. While initial effects may be neutral or adverse, long-term benefits accrue over weeks to months with patient perseverance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.

JACC. Heart failure·2021
Same author

Impact of Geographic Region on the COMMANDER-HF Trial.

JACC. Heart failure·2021
Same author

The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure.

Journal of cardiac failure·2021
Same author

Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus.

Cardiovascular endocrinology & metabolism·2020
Same author

Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF.

European journal of heart failure·2020
Same author

The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.

European heart journal·2020

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are a cornerstone therapy for heart failure with left ventricular (LV) systolic dysfunction.
  • Their role is primarily in tertiary prevention, not acute heart failure crisis management.

Purpose of the Study:

  • To elucidate the time course of beta-blocker effects in heart failure.
  • To emphasize the need for patient understanding and adherence to maximize therapeutic benefits.

Main Methods:

  • Review of existing clinical evidence and trial data on beta-blocker therapy in heart failure.
  • Analysis of the temporal relationship between beta-blocker initiation and clinical outcomes.

Main Results:

  • Initial beta-blocker therapy may show neutral or adverse effects, but significant benefits emerge gradually over weeks to months.

Related Experiment Videos

  • Carvedilol may demonstrate benefits within days in severe heart failure cases.
  • Early initiation of beta-blockers enhances treatment effectiveness and patient acceptance.

    • Conclusions:

    • Beta-blockers are crucial for managing heart failure due to LV systolic dysfunction, requiring patience and education for optimal outcomes.
    • Ongoing trials are investigating beta-blocker efficacy in elderly patients and those with preserved LV function.
    • Further research is needed to compare specific beta-blockers and optimize current dosage recommendations.